|
Bipartisan Bill Would Boost Exclusivity, Review Speed for Some Combo Drug Products
New fixed-dose drug combinations that include at least two INDs and target a serious or life-threatening disease could be eligible for an additional six months of marketing exclusivity and priority review under a new bipartisan-supported bill sponsored by Rep. Brian Bilbray (R-Calif.).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives